# A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

Source: https://onco.cc/trials/nct03873402/  
OnCo record `nct03873402` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Nivolumab, Ipilimumab in renal cell carcinoma, run by Bristol-Myers Squibb, active and no longer recruiting.

## Summary

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer is a phase 3 interventional study registered as NCT03873402 by Bristol-Myers Squibb, with 437 participants enrolled, started 2019-06-21 and due to reach its primary completion in 2027-03-11. Interventions recorded: Nivolumab, Ipilimumab, Ipilimumab placebo. Conditions listed: Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03873402
- Phase: 3
- Setting: A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy for Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors
- Sponsor: Bristol-Myers Squibb
- Enrolled: 437

## Sources

- ClinicalTrials.gov NCT03873402: https://clinicaltrials.gov/study/NCT03873402

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct03873402.json